Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Clinical HypertensionOpen Access

A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NLNa LiZYZhixin YangQYQuan Yuan

Discussion

Loading...

Member takes

Overview

Risk stratification identifies optimal candidates for intensive blood pressure treatment, suggesting improved outcomes in hypertension management.

Key Points

  • The risk stratification model effectively identifies patients likely to benefit from intensive blood pressure treatment, enhancing personalized care.
  • C-indices for training and validation in the model were 0.7354 and 0.6894, respectively, demonstrating good discrimination.
  • Intensive blood pressure treatment significantly reduced cardiovascular event rates in the medium-risk and high-risk groups, confirming its efficacy.
  • No significant increase in severe adverse events was observed, indicating that the stratification approach is safe for patients.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68c23fc3b210217d647976cbhttps://doi.org/10.1111/jch.70098
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines2016 · 29 citations
  2. 2Effects of intensive blood pressure control on cardio-kidney outcomes by KDIGO risk categories: a Post Hoc analysis of ACCORD-BP and SPRINT trials2026
  3. 3Effects of Intensive Systolic Blood Pressure Control on Kidney Outcomes in Patients With and Without <scp>CKD</scp>: A Post Hoc Analysis of <scp>SPRINT</scp> and <scp>ACCORD</scp>‐<scp>BP</scp> Trials2025
  4. 4Effect of Intensive Blood Pressure Control in Patients with Resistant Hypertension: Insights from the STEP Trial.2025
  5. 5Metabolic health and cardiovascular outcomes in treated hypertension: a secondary analysis of SPRINT2026